Healthcare
Inovio Pharmaceuticals, Inc.(INO)
Live Price
Offline$1.13
+1.80% today
1Y Change
-50.67%
Window
Jun 26, 2025 โ Jun 16, 2026
- Market Cap
- $60.00M
- Revenue Growth
- -70.0%
- EPS Growth
- +54.2%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 26, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Inovio Pharmaceuticals, Inc. (INO) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $1.13 and down 50.7% across the available one-year price window (Jun 26, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -70.0%, EPS growth of +54.2%, a dividend yield of 0.0%. What stands out right now is revenue -70.0%, EPS +54.2%, free cash flow +15.0% with operating margin -132871.3% and ROIC -259.4%. Valuation already assumes a fairly strong business story at price/sales 918.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines INO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-70.0% vs +7.6% peer median
Operating Margin
Below sector median
-132871.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -70.0% and EPS is at +54.2%, with operating margin around -132871.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -5.0% | -13.5% | -22.7% |
2026 Mar 12, 2026 | +183.8% | -1.2% | -1.8% | -36.9% |
2025 Nov 10, 2025 | +13.7% | -7.0% | -7.9% | +1.4% |
Benchmark Edge
INO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INO Max Drawdown
-63.41%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INO and SPY.
Company Overview
Inovio Pharmaceuticals, Inc.
NASDAQ Global Select
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
- Leadership
- Jacqueline E. Shea
- IPO Date
- Dec 8, 1998
- Employees
- 134
- Street Address
- 660 West Germantown Pike
- Mailing
- Plymouth Meeting, PA, 19462
- Region
- Plymouth Meeting, PA, US
- Reporting Currency
- USD
- Investor Line
- 267 440 4200
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 918.5
- Price/Book
- 21.8
Growth
- Revenue
- -70.0%
- EPS
- +54.2%
- Free Cash Flow
- +15.0%
Profitability
- Gross Margin
- -2189.0%
- Operating Margin
- -132871.3%
- Net Margin
- -130000.0%
- ROE
- -353.4%
- ROIC
- -259.4%
Balance Sheet
- Debt/Equity
- 0.39
- Current Ratio
- 1.40
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.